Abstract
Initial Safety and Efficacy Results from the Phase II, Multicenter, Open-Label Solace-Kids Trial of Crizanlizumab in Adolescents with Sickle Cell Disease (SCD)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have